4/23/2013

The pharmaceutical industry's potential liability widened after some U.S. states showed more aggressiveness in accusing drugmakers of deceptive marketing. Certain states have opted to act alone, which has led to heavy settlements and single-state awards. PhRMA Senior Vice President Matthew Bennett said "imposing state-law penalties on manufacturers for alleged violations of [federal drug law] raises serious legal and constitutional questions."

Related Summaries